{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:11:06Z","timestamp":1793923866078,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jclinepi.2025.111841","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T10:52:43Z","timestamp":1748083963000},"page":"111841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The importance of reporting computed tomography scan intervals in real-world oncology studies: a simulation analysis of afatinib in advanced-stage non-small cell lung cancer"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-2285","authenticated-orcid":false,"given":"Sasiwimon","family":"Iwsakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-8268","authenticated-orcid":false,"given":"Sarayut Lucien","family":"Geater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jclinepi.2025.111841_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"24","key":"10.1016\/j.jclinepi.2025.111841_bib2","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1002\/sim.6529","article-title":"Bias in progression-free survival analysis due to intermittent assessment of progression","volume":"34","author":"Zeng","year":"2015","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.jclinepi.2025.111841_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2217\/imt-2023-0002","article-title":"Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results","volume":"15","author":"Verschueren","year":"2023","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111841_bib4","article-title":"Systematic evaluation of the efficacy\u2013effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer","volume":"52","author":"van der Welle","year":"2018","journal-title":"Eur Respir J"},{"issue":"27","key":"10.1016\/j.jclinepi.2025.111841_bib5","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111841_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111841_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jclinepi.2025.111841_bib8","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s00432-020-03501-6","article-title":"Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study","volume":"147","author":"Bilgin","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jclinepi.2025.111841_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2018.10.028","article-title":"Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGiDo)","volume":"127","author":"Halmos","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111841_bib10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1186\/s12885-019-6107-1","article-title":"Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study","volume":"19","author":"Ho","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jclinepi.2025.111841_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211035710","article-title":"First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer","volume":"13","author":"Huang","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111841_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/cancers14020316","article-title":"Afatinib treatment alone or with bevacizumab in a real-world cohort of non-small cell lung cancer patients with epidermal growth factor receptor mutation","volume":"14","author":"Kuo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.jclinepi.2025.111841_bib13","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.21037\/tlcr-21-501","article-title":"Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea","volume":"10","author":"Lee","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"52","key":"10.1016\/j.jclinepi.2025.111841_bib14","doi-asserted-by":"crossref","first-page":"90430","DOI":"10.18632\/oncotarget.19563","article-title":"Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"issue":"57","key":"10.1016\/j.jclinepi.2025.111841_bib15","doi-asserted-by":"crossref","first-page":"97602","DOI":"10.18632\/oncotarget.18746","article-title":"The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111841_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253335","article-title":"Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: a retrospective observational cohort study","volume":"16","author":"Ng","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jclinepi.2025.111841_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1186\/s12885-021-08445-9","article-title":"An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-na\u00efve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations","volume":"21","author":"Park","year":"2021","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111841_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12032-019-1278-9","article-title":"Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer","volume":"36","author":"Tanaka","year":"2019","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111841_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-021-00859-6","article-title":"A phase IIIb open-label, single-arm study of afatinib in EGFR TKI-na\u00efve patients with EGFRm+ NSCLC: final analysis, with a focus on patients enrolled at sites in China","volume":"17","author":"Tu","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.jclinepi.2025.111841_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920946156","article-title":"The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation","volume":"12","author":"Wu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"16","key":"10.1016\/j.jclinepi.2025.111841_bib21","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1002\/cam4.2571","article-title":"Optimal frequency of scans for patients on cancer therapies: a population kinetics assessment","volume":"8","author":"Stewart","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111841_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/pds.5323","article-title":"Differential frequency in imaging-based outcome measurement: Bias in real-world oncology comparative-effectiveness studies","volume":"31","author":"Adamson","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"282","key":"10.1016\/j.jclinepi.2025.111841_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111841_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B (Methodological)"},{"issue":"4","key":"10.1016\/j.jclinepi.2025.111841_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1198\/000313004X5419","article-title":"A review of software packages for analyzing correlated survival data","volume":"58","author":"Kelly","year":"2004","journal-title":"Am Statistician"},{"issue":"4","key":"10.1016\/j.jclinepi.2025.111841_bib26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/1536867X19893639","article-title":"Multilevel mixed-effects parametric survival analysis: estimation, simulation, and application","volume":"19","author":"Crowther","year":"2019","journal-title":"Stata J"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111841_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1536867X1301300204","article-title":"A command for Laplace regression","volume":"13","author":"Bottai","year":"2013","journal-title":"Stata J"},{"key":"10.1016\/j.jclinepi.2025.111841_bib28","author":"Bottai"},{"issue":"4","key":"10.1016\/j.jclinepi.2025.111841_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/bimj.200900310","article-title":"Laplace regression with censored data","volume":"52","author":"Bottai","year":"2010","journal-title":"Biom J"},{"issue":"7","key":"10.1016\/j.jclinepi.2025.111841_bib30","article-title":"The frequency of assessment of progression in randomized oncology clinical trials","volume":"5","author":"Haslam","year":"2022","journal-title":"Cancer Rep"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111841_bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jnci\/djk091","article-title":"When you look matters: the effect of assessment schedule on progression-free survival","volume":"99","author":"Panageas","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jclinepi.2025.111841_bib32","author":"Frumento"},{"issue":"15_suppl","key":"10.1016\/j.jclinepi.2025.111841_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.tps7614","article-title":"ASPIRATION: phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)","volume":"30","author":"Park","year":"2012","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111841_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089543562500174X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089543562500174X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:36:01Z","timestamp":1755650161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089543562500174X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":34,"alternative-id":["S089543562500174X"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.111841","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of reporting computed tomography scan intervals in real-world oncology studies: a simulation analysis of afatinib in advanced-stage non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.111841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111841"}}